CCMG
ADPT icon

Clark Capital Management Group’s Adaptive Biotechnologies ADPT Stock Holding History

Clark Capital Management Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,204
Closed -$491K – 331
2021
Q1 		$491K Sell
12,204
-50
-0.4% -$2.71K 0.01% 296
2020
Q4 		$725K Buy
+12,254
New +$632K 0.01% 278

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clark Capital Management Group's ADPT Position: Q2 2021 in Review

Clark Capital Management Group sold out of Adaptive Biotechnologies (ADPT) in Q2 2021, closing a stake of 12,204 shares — an estimated $491K sold.

Clark Capital Management Group first reported a position in ADPT in Q4 2020 and held it in 2 quarters. The position peaked at $725K in Q4 2020. 230 funds tracked by Wall St. Rank hold ADPT as of Q2 2021.

  • Clark Capital Management Group reported no remaining Adaptive Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Clark Capital Management Group sold 12,204 Adaptive Biotechnologies shares in Q2 2021, an estimated $491K.
  • Clark Capital Management Group first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 2 quarters.
  • Clark Capital Management Group's Adaptive Biotechnologies position peaked at $725K in Q4 2020.
  • 230 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2021.

Based on Clark Capital Management Group's 13F filing for Q2 2021, filed 2 Aug 2021.